News headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1899076839848 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

Fate Therapeutics (NASDAQ FATE) opened at $4.15 on Tuesday. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a 12-month low of $2.40 and a 12-month high of $5.68.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts predict that Fate Therapeutics will post -0.99 earnings per share for the current fiscal year.

FATE has been the subject of a number of research reports. ValuEngine downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 7th. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Thursday, August 17th. Leerink Swann reaffirmed an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Friday, September 8th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Thursday, October 12th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $6.79.

ILLEGAL ACTIVITY WARNING: “Fate Therapeutics (FATE) Earning Somewhat Favorable Media Coverage, Study Finds” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/14/fate-therapeutics-fate-earning-somewhat-favorable-media-coverage-study-finds.html.

In other news, insider Daniel D. Shoemaker sold 13,225 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Cindy Tahl sold 8,091 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.85, for a total value of $31,150.35. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by company insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.